Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031590 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
A Phase 2 study, sponsored by Children's Hospital of Philadelphia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00031590 is a Phase 2 study that was terminated before completion, run by Children's Hospital of Philadelphia. The registered enrollment target is 30 participants.
The verdict
NCT00031590, a Phase 2 study, was terminated before completion, sponsored by Children's Hospital of Philadelphia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but also damages normal cells in the developing brains of children. Combining low-dose radiation therapy in combination with chemotherapy should be effective in treating medulloblastoma while avoiding the long-term side effects of giving higher dose radiation to children with newly diagnosed average risk medulloblastoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Vincristine
- DRUG Lomustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-04 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031590
The ClinicalTrials.gov registry entry for NCT00031590 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00031590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031590 about?
NCT00031590 is a clinical study titled "Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but also damages normal cells in the developing brains of children. Combining low-dose radiation therapy in combination with chemotherapy should be effective in treating medulloblastoma while avoiding the long-term side effe...
What is the current status of trial NCT00031590?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2001-04. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00031590?
The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), Etoposide (DRUG), Vincristine (DRUG), Lomustine (DRUG).
Who is sponsoring clinical trial NCT00031590?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.